No Data
No Data
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
HK stocks unusual| Hec cj pharm (01558) rose more than 4% against the market. Results of Hang Seng Index quarterly review is approaching, and the company is expected to enter the Hong Kong stock connect list in September.
Hec CJ Pharm (01558) rose more than 4% against the market, as of press time, up 3.33% at HKD 9.32, with a turnover of HKD 11.2045 million.
[Brokerage Focus] Citic Securities: HSCEI welcomes the results of the new round of quarterly reviews on August 16, and it is expected that 19 symbols will enter the Hong Kong Stock Connect.
Jingu Financial News | Citic Securities stated that the Hang Seng Index will undergo a new review on August 16th, and the adjustment will officially take effect on September 9th. The Hong Kong stock connect will also correspondingly adjust. The bank expects to have 19 symbols to be included in the Hong Kong stock connect, of which the technology, optional consumer, and energy sectors have higher market capitalization weight. Broken down by industry, including 5 technology companies: Maipu Times (02556), Quchizhu Group (00917), Zhixing Automotive Technology (01274), Shengneng Group (02459), and Yisou Technology (02550); 3 optional consumer enterprises: Auto Street (02443), ...
Stock market fluctuations | HEC CJ Pharm (01558) rose more than 2%. The company is expected to be included in the Hong Kong stock exchange, which may bring opportunities for valuation and liquidity improvement.
Hec cj pharm (01558) rose more than 2% and as of writing, rose 2.04%, to HKD 9.02, with a turnover of HKD 1.1493 million.
CITIC Securities: Hang Seng Index will welcome a new round of review results, and Alibaba-SW is expected to be included in the Hong Kong Stock Connect.
CITIC Securities released a research report stating that the Hang Seng Index will undergo a new round of review results on August 16, and the adjustment will take effect on September 9. Hong Kong Stock Connect will also be adjusted accordingly. The bank predicts that there will be 20 symbols included in the Hong Kong Stock Connect, among which the information technology, optional consumer, and energy sectors have higher market value weights. If Alibaba-SW (09988) successfully converts to a dual primary listing by the end of August, it may be included in Hong Kong Stock Connect in this review. The bank also recommends investors to pay attention to timing opportunities between the announcement date of the Hang Seng Index and the effective date of the Hong Kong Stock Connect. In addition, due to some arbitrage funds or before the effective date of the Hong Kong Stock Connect
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
No Data